The PhRMA Foundation Announces New Board Members

The PhRMA Foundation Announces New Board Members

WASHINGTON, November 29, 2022 /PRNewswire/ — The PhRMA Foundation today announced the appointment to its Board of Trustees of Aida HabtesionMD, Chief Medical Officer at Pfizer, Maha Radhakrishnan, MD, Chief Medical Officer at Biogen, George AddonaPhD, Senior Vice President and Head of Discovery, Preclinical and Translational Medicine at Merck Research Laboratories, and Lori Reilly, EsqDirector of Operations at PhRMA.

PhRMA Foundation logo

PhRMA Foundation logo

The PhRMA Foundation is a 57-year-old nonprofit organization that promotes biopharmaceutical innovation and value-driven healthcare by investing at the frontiers of research. The Foundation catalyzes the careers of promising scholars through competitive, peer-reviewed grants and fellowships.

“These new board members bring to the PhRMA Foundation a diversity of experience and perspective that is essential as we enter the next era of change for the biopharmaceutical industry,” said Amy M. Miller, PhD, President of the PhRMA Foundation. “I look forward to working with our Board of Directors to chart the way forward for the organization and support the rapidly evolving field.”

As Chief Medical Officer, Dr. Habtezion leads Pfizer’s global medical and safety organization responsible for ensuring that patients, physicians and regulators receive information on the safe and appropriate use of Pfizer medicines. . Prior to joining Pfizer, she was a practicing physician and scientist at from Stanford University School of Medicine, where she led a large translational research laboratory focused on understanding disease mechanisms and identifying potential immune therapeutic targets for inflammatory pancreatic and intestinal diseases and their long-term complications such as cancer.

“As a long-time academic researcher who has made the transition to industry, I greatly appreciate the PhRMA Foundation’s unique role in funding promising young scientists conducting research that helps initiate future efforts at the biopharmaceutical industry to deliver new drugs to patients,” said Dr. Habtezion. “I look forward to partnering with the Foundation Board and staff to ensure the continued success of this respected organization.”

Biogen’s Dr. Radhakrishnan is one of the foremost experts in medical affairs strategy and health outcomes research and currently serves as Chief Medical Officer. She brings extensive experience in overseeing external engagement approaches with academic institutions, key opinion leaders, patient advocacy groups, payers and regulators. Prior to joining Biogen, Dr. Radhakrishnan held leadership positions at Sanofi, Bioverativ, Bristol Myers Squibb, United Health Group and Cephalon.

“By investing in promising scientists and researchers, the PhRMA Foundation plays a fundamental role in helping the biopharmaceutical industry adapt to changing realities,” said Dr. Radhakrishnan. “With this evolution, PhRMA Foundation programs can help industry meet many challenges. One thing remains clear: we all need to unite in industry to advance science and improve meaningful and measurable outcomes for patients. patients.”

Dr. Addona has been with Merck since 2008 and is currently overseeing the early stage pipeline, first human studies and biomarker development. Previously, he was Vice President of Quantitative Biosciences, playing a critical role in Merck’s drug discovery organization by leading a multidisciplinary team focused on preclinical programs across all of the company’s therapeutic areas. Prior to joining Merck, he held positions at Novartis and Praecis Pharmaceuticals.

“Our industry is at an inflection point where emerging technologies and new therapeutic modalities are creating exciting opportunities in drug and vaccine discovery and development,” said Dr. Addona. “I look forward to working with my fellow PhRMA Foundation board members to foster innovative research and inspire a diverse new generation of biopharmaceutical scientists.”

Due to a change in the Foundation’s bylaws, Ms. Reilly joins the Foundation’s Board of Directors as an ex-officio PhMRA representative. A long-time leader in developing and promoting practical policy solutions that bring medicines to patients, Ms. Reilly oversees PhRMA’s advocacy and alliance-building work and provides strategic leadership to the organization and its constituents. members. Prior to her 20 years with the PhRMA, she was an advisor to the US House Committee on Commerce and a member of the House Ways and Means Committee.

“Research is essential to advancing new medicines and informing the policy environment that paves the way for patient access to these medicines,” said Ms. Reilly. “The PhRMA Foundation fills a critical niche for the biopharmaceutical industry, helping to fuel innovation and develop thoughtful approaches to promote a value-driven healthcare system.”

About the PhRMA Foundation

The PhRMA Foundation promotes biopharmaceutical innovation and value-driven healthcare by investing at the frontiers of research. The Foundation catalyzes the careers of promising researchers through competitive, peer-reviewed grants and fellowships in the fields of drug delivery, drug discovery, translational medicine, value assessment and health outcomes research. Since its creation in 1965, the Foundation has awarded more than $110 million to more than 2,700 researchers from diverse backgrounds in more than 300 institutions. To learn more, please visit



View original content to download multimedia:

SOURCE PhRMA Foundation

#PhRMA #Foundation #Announces #Board #Members

Leave a Comment

Your email address will not be published. Required fields are marked *